Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
INCHEON, South Korea, Aug. 28, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company’s three-dimensional, long-term growth strategy across capacity, portfolio, and geographic expansion. The company plans to allocate approximately KRW 2.71 trillion of the offering […]







